Showing 4281-4290 of 7767 results for "".
- Almirall and Inserm Transfert Collaborate to Develop Innovative Treatments for Vitiligohttps://practicaldermatology.com/news/almirall-and-inserm-transfert-collaborate-to-develop-innovative-treatments-for-vitiligo/2461198/Almirall, S.A. and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), have entered into a licensing agreement and research collaboration to advance treatment options for vitiligo. The partnership, signed by
- New Two-Year Data on Deucravacitinib Reinforce Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-two-year-on-bms-deucravacitinib-data-reinforce-efficacy-and-safety-profile-in-treatment-of-moderate-to-severe-plaque-psoriasis/2461191/Bristol Myers Squibb shared new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. Clinical efficacy was maintained through u
- Indoor Tanning Ban Could Slash Melanoma Deathshttps://practicaldermatology.com/news/indoor-tanning-ban-could-slash-melanoma-deaths/2461190/An indoor tanning ban in England would reduce melanoma deaths, according to a study by University of Manchester researchers. By tracking the projected impact on the 618,000 18-year-olds living in England in 2019, the research team showed that a ban on indoor tanning would resu
- Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Diseasehttps://practicaldermatology.com/news/ready-for-prime-time-ampels-blood-tests-may-predict-drug-options-for-inflammatory-skin-disease/2461179/Ampel BioSolutions machine learning approach can characterize disease activity from gene expression data obtained from patient skin biopsy and may revolutionize the way doctors treat inflammatory skin diseases, according to research published in Science Advances. The lab test
- Lumenis Has Launched triLift for Facial Stimulationhttps://practicaldermatology.com/news/lumenis-has-launched-trilift-for-facial-stimulation/2461173/Lumenis Be, Ltd., has launched triLift, a facial stimulation device targeting three aging elements—structure, contour, and texture—by treating the three tissue layers. The device affects the muscl
- FDA Approves Sol-Gel Technologies' and Galderma's Epsolay for Rosaceahttps://practicaldermatology.com/news/fda-approves-sol-gel-technologies-and-galdermas-epsolay-for-rosacea/2461170/The FDA has approved Sol-Gel Technologies' Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults. The benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules. The silica-based s
- Milestone Alert: R2 Technologies Ships Out 100 GLACIAL Rx Deviceshttps://practicaldermatology.com/news/milestone-alert-r2-technologies-ships-out-100-glacial-devices/2461169/R2 Technologies Inc. has shipped 100 GLACIAL Rx devices across the globe. To-date customers have delivered more than 15,000 GLACIAL treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this mileston
- Study: Improved Survival Seen for DecisionDx-Melanoma Tested Patientshttps://practicaldermatology.com/news/study-improved-survival-seen-for-decisiondx-melanoma-tested-patients/2461168/Melanoma patients tested with DecisionDx-Melanoma plus traditional clinicopathologic factors showed improved survival compared to patients tested with only traditional clinicopathologic factors available to determine their treatment and follow-up plan, according to data presented the 18th Europea
- Castle's Non-Invasive Gene Expression Profile Test Can Predict Response to Systemic Therapy in Patients with Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/castles-gene-expression-profile-test-can-predict-response-to-systemic-therapy-in-patients-with-inflammatory-skin-diseases/2461163/Castle Biosciences, Inc.’s non-invasive skin scraping technique produces sufficient ribonucleic acid (RNA) to assess reproducible gene expression for its inflammatory skin disease pipeline test, according to a poster was presented at the 4th Annual Revolutionizing Atopic Der
- TOOsonix System ONE-M BCC Clinical Trial Updatehttps://practicaldermatology.com/news/toosonix-system-one-m-bcc-clinical-trial-update/2461162/The first basal cell carcinoma (BCC) patients have been treated with TOOsonix A/S’s System ONE-M device. The TOOsonix high-intensity focused ultrasound (HIFU) delivers highly accurate doses of energy to focal points in a chosen depth. It operates at 20 MHz to